According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Other equities analysts also recently issued research reports about the stock. Lake Street Capital started coverage on shares of Sientra in a report on Thursday, April 14th. They issued a buy rating and a $8.00 price target on the stock. UBS Group cut their price target on shares of Sientra from $10.00 to $8.00 and set a buy rating on the stock in a report on Tuesday, March 29th. Stifel Nicolaus cut their price target on shares of Sientra from $11.00 to $7.00 and set a buy rating on the stock in a report on Thursday, March 24th. Maxim Group reiterated a buy rating and issued a $5.00 price target on shares of Sientra in a report on Friday, May 13th. Finally, Canaccord Genuity Group cut their price target on shares of Sientra from $10.00 to $8.00 and set a buy rating on the stock in a report on Tuesday, March 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $6.89.
Sientra (NASDAQ:SIEN – Get Rating) last posted its quarterly earnings data on Wednesday, March 23rd. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). Sientra had a negative net margin of 71.61% and a negative return on equity of 498.54%. The company had revenue of $22.65 million for the quarter, compared to analyst estimates of $22.50 million. During the same quarter last year, the company earned ($0.38) EPS. Sell-side analysts expect that Sientra will post -0.9 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Mirabella Financial Services LLP purchased a new position in shares of Sientra during the 1st quarter valued at approximately $26,000. State Street Corp lifted its position in shares of Sientra by 3.9% during the 1st quarter. State Street Corp now owns 1,018,410 shares of the medical instruments supplier’s stock valued at $2,261,000 after buying an additional 38,403 shares in the last quarter. Engineers Gate Manager LP lifted its position in shares of Sientra by 94.9% during the 1st quarter. Engineers Gate Manager LP now owns 166,872 shares of the medical instruments supplier’s stock valued at $370,000 after buying an additional 81,266 shares in the last quarter. Archon Capital Management LLC purchased a new position in shares of Sientra during the 1st quarter valued at approximately $2,160,000. Finally, Renaissance Technologies LLC lifted its position in shares of Sientra by 328.2% during the 1st quarter. Renaissance Technologies LLC now owns 208,770 shares of the medical instruments supplier’s stock valued at $463,000 after buying an additional 160,018 shares in the last quarter. Hedge funds and other institutional investors own 82.42% of the company’s stock.
About Sientra (Get Rating)
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
- Get a free copy of the StockNews.com research report on Sientra (SIEN)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.